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Patient Blood Management
Success and Potential in the Future
Donat R. Spahn, MD, FRCA
P reoperative anemia,
1 exaggerated blood loss,2 and allogeneic red blood cell (RBC) transfusions3
are individual and intertwined factors that adversely affect patient outcome. They are modifiable
and represent the 3 pillars of patient blood management (PBM)—a comprehensive and interdisci-
plinary concept that aims at pre-emptively reducing the need for RBC transfusions to improve patient
safety and outcome.4 The 3 pillars of PBM are: treatment of preoperative anemia, reduction of
perioperative RBC loss, and optimization of the physiologic anemia tolerance including the use of
restrictive transfusion triggers.
Meybohm et al, in this issue of the Journal, show that the implementation of PBM in all
surgical disciplines in 4 German University Hospitals is safe and reduces RBC transfusions by 17%
and acute renal failure by 30%.5 It is important to stress that this represents real-life data because all
surgical patients were included without any exclusion criteria. Safety, the primary outcome, was
assessed as the composite outcome of in-hospital mortality, myocardial infarction, ischemic stroke,
acute renal failure, pneumonia, or sepsis. It is highly interesting (Tables 3 and 5 of the paper5) that
RBC transfusions and the primary outcome progressively decreased the longer PBM had been
implemented. I hypothesize that the full benefit of PBM had not yet been achieved 1 to 2 years after
PBM implementation because the RBC transfusion rate also progressively decreased over several
years after the implementation of a PBM program in Western Australia.6
Given the multitude of measures of a comprehensive PBM program, it is not astonishing that
some centers did not yet fully succeed in the implementation of certain PBMmeasures (Fig. 1B of the
paper5). Particularly well implemented was the emphasis on surgical hemostasis and the point-of-care
diagnostic for coagulation monitoring. In contrast, relatively little progress was achieved so far in the
extended preoperative diagnostics and treatment of anemia. Consequently, the anemia rate at admission
remained high at a staggering 35% and admission hemoglobin concentration remained stable. With
unchanged discharge hemoglobin, but reducedRBC transfusions, the perioperativeRBC lossmust have
gonedown.The exact reasonhasnot been formally analyzed in this study, but likely represents a reduced
surgical blood loss due to improved surgical hemostasis and coagulation monitoring and treatment.
The yet unchanged preoperative anemia rate represents a promising field for future research
and unmet PBM potential. Preoperative anemia affects approximately 30% of patients and is
associated with increased perioperative mortality (20%–40%), increased morbidity (30%), more
RBC transfusions, and prolonged length of hospital stay.1,7 Anemia treatment is efficacious in
orthopedic,8,9 cardiac,10 and abdominal surgery,11,12 not only in reducing RBC transfusions but also
in reducing acute kidney injury, infections, and length of hospital stay.8–12 Why then is preoperative
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anemia treatment not better implemented yet in clinical practice?
The most important reasons are that many physicians:
1. insufficiently know the definition of anemia, that is, a hemo-
globin<12 g/dL for women and a hemoglobin<13 g/dL for men,
2. do not fully recognize the perioperative burden of even mild
anemia, thst is, a hemoglobin of 10 to 12 g/dL for women and a
hemoglobin of 10 to 13 g/dL for men,
3. report patients only late to anesthesiologists and therefore there
seems to be little time for anemia detection and treatment,
4. perceive anemia treatment to be costly and requiring up-
front investment.
In addition, systematic preoperative anemia treatment is
indeed logistically demanding in large hospitals.6 Nevertheless,
we are to invest efforts into a better anemia treatment in the future.
The Duke Perioperative Enhancement Team recently delineated in
detail how to develop and implement a preoperative anemia clinic
successfully.13 In addition to early referral, ‘‘intelligent scheduling
systems’’ are conceivable. Such systems would allow the scheduling
of elective patients for operations with an expected blood loss of
more than say 500mL or a probability of RBC transfusion greater
than 10% only if preoperative anemia had been investigated and
successfully treated. Preoperative anemia treatment programs thus
may finally become standard clinical practice.6,14
Unfortunately, the authors did not analyze costs. This is
another important aspect for the acceptance of a new treatment
paradigm not only for physicians but also for hospital administrators
and third-party payers. The authors are encouraged to use their data
set for a formal cost analysis because the introduction of PBM
programs and PBM measures have been shown to be cost-saving
in the past in smaller studies.13,15–18
I congratulate the authors of this study and all the participating
physicians for their tremendous effort in implementing PBM system-
atically in their hospitals. They have proven safety and benefits of
this concept. The full potential of PBM, however, is certainly larger,
and the study clearly highlights areas of future points of action, first
of which may be the implementation of structures for systematic
preoperative anemia treatment.
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